Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy

Oncologist

Volumn 13, Issue 8, 2008, Pages 911-920

  Estilo, Cherry L ^a   Van Poznak, Catherine H ^b   Wiliams, Tijaana ^a   Bohle, George C ^a   Lwin, Phyu T ^a   Zhou, Qin ^a   Riedel, Elyn R ^a   Carlson, Diane L ^a   Schoder, Heiko ^a   Farooki, Azeez ^a   Fornier, Monica ^a   Halpern, Jerry L ^a   Tunick, Steven J ^a   Huryn, Joseph M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Bisphosphonate therapy; Osteonecrosis of the jaw; Pamidronate; Zoledronic acid

Indexed keywords

BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; PAMIDRONIC ACID; THALIDOMIDE; ZOLEDRONIC ACID;

ADVANCED CANCER; ANEMIA; ARTICLE; BLOOD CLOTTING DISORDER; BONE METASTASIS; BONE NECROSIS; BREAST CANCER; DRUG SAFETY; HUMAN; JAW DISEASE; MADIBLE OSTEONECROSIS; MAJOR CLINICAL STUDY; MANDIBLE OSTEONECROSIS; MAXILLA OSTEONECROSIS; MONOTHERAPY; MOUTH HYGIENE; MULTIPLE MYELOMA; OSTEOARTHRITIS; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SICKLE CELL ANEMIA; STATISTICAL SIGNIFICANCE; THALASSEMIA; TREATMENT DURATION; TREATMENT OUTCOME;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; JAW; JAW NEOPLASMS; MALE; MANDIBLE; MAXILLA; OSTEONECROSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 50649114676     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0091     Document Type: Article

References (33)

1. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80(suppl 8):1588-1594.
2. Body JJ. Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer 2003;97(suppl 3):859-865.
3. Bagan JV, Murillo J, Jimenez Y et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: Series of 10 cases. J Oral Pathol Med 2005;34:120-123.
4. Carter GD, Goss AN. Bisphosphonates and avascular necrosis of the jaws. Aust Dent J 2003;48:268.
5. Durie BGM, Katz M, McCoy J et al. Osteonecrosis of the jaws in myeloma: Time dependent correlation with Aredia® and Zometa® use. Blood 2004;104:756.
6. Estilo CL, Van Poznak CH, Williams T et al. Osteonecrosis of the maxilla and mandible in patients treated with bisphosphonates: A retrospective study. J Clin Oncol 2004;22:8088a.
7. Marx RE. Pamidronate (Aredia®) and zoledronate (Zometa®) induced avascular necrosis of the jaws: A growing epidemic [letter]. J Oral Maxillofac Surg 2003;61:1115-1117.
8. Van Poznak C, Estilo C. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates. Oncology (Williston Park) 2006;20:1053-1062; discussion 1065-1066.
9. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: Background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:433-441.
10. Hoff AO, Toth BB, Altundag K et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 2006;24:8528a.
11. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates [letter]. N Engl J Med 2005;353:99-102.
12. Bamias A, Kastritis E, Bamia C et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 2005;23:8580-8587.
13. Assouline-Dayan Y, Chang C, Greenspan A et al. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 2002;32:94-124.
14. Hansen T, Kunkel M, Springer E et al. Actinomycosis of the jaws - histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch 2007;451:1009-1017.
15. Ruggiero SL, Mehrotra B, Rosenberg TJ et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534.
16. Migliorati CA, Schubert MM, Peterson DE et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: An emerging oral complication of supportive cancer therapy. Cancer 2005;104:83-93.
17. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: Expert panel recommendations. J Am Dent Assoc 2006;137:1144-1150.
18. Marx RE, Sawatari Y, Fortin M et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteoporosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-1575.
19. Green JR. Preclinical pharmacology of zoledronic acid. Semin Oncol 2002; 29(suppl 21):3-11.
20. O'Connor, Padmanabhan A, Wilding G et al. Bisphosphonate-induced osteonecrosis of the jaw: Risk factors and diagnostic utility of bone scans. J Clin Oncol 2007;25(suppl 20):9052.
21. Chiandussi S, Biasotto M, Dore F et al. Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofac Radiol 2006;35:236-243.
22. Boissier S, Ferreras M, Peyruchaud O et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60:2949-2954.
23. Croucher PI, De Hendrik R, Perry MJ et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003;18:482-492.
24. Fournier P, Boissier S, Filleur S et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in ventral prostate in castrated rats. Cancer Res 2002;62:6538-6544.
25. Wood J, Bonjean K, Ruetz S et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-1061.
26. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
27. Bauer SM, Bauer RJ, Velazquez OC. Angiogenesis, vasculogenesis, and induction of healing in chronic wounds. Vasc Endovascular Surg 2005;39:293-306.
28. Gerber HP, Ferrara N. Angiogenesis and bone growth. Trends Cardiovasc Med 2000;10:223-228.
29. Aragon-Ching JB, Ning YM, Latham L et al. Osteonecrosis of the jaw (ONJ) in androgen-independent prostate cancer (AIPC) patients receiving ATTP (bevacizumab, docetaxel, thalidomide and prednisone). J Clin Oncol 2007;25:19594a.
30. Weitzman R, Sauter N, Eriksen EF et al. Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients - May 2006. Crit Rev Oncol Hematol 2007;62:148-152.
31. Khosla S, Burr D, Cauley J et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-1491.
32. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-376.
33. Migliorati CA, Casiglia J, Epstein J et al. Managing the care of patients with bisphosphonate-associated osteonecrosis: An American Academy of Oral Medicine position paper. J Am Dent Assoc 2005;136:1658-1668.